Combining XR5944 with 5-FU and Irinotecan for Colon Cancer Treatment
Author Information
Author(s): Harris S M, Mistry P, Freathy C, Brown J L, Charlton P A
Primary Institution: Xenova Ltd
Hypothesis
Can XR5944 enhance the antitumor effects of 5-fluorouracil and irinotecan in colon cancer treatment?
Conclusion
XR5944 combined with 5-FU or irinotecan shows significant antitumor activity in colon cancer models.
Supporting Evidence
- XR5944 showed significant antitumor activity in HT29 xenografts.
- Combination therapy with XR5944 and 5-FU resulted in better efficacy than either drug alone.
- Sequential administration of drugs improved the overall treatment response.
Takeaway
Researchers found that a new drug called XR5944 works better when used with other cancer drugs to fight colon cancer.
Methodology
The study evaluated the cytotoxicity of XR5944 in combination with 5-FU and irinotecan using in vitro assays and in vivo xenograft models.
Potential Biases
Potential bias in drug interactions due to the specific cell lines used.
Limitations
The study primarily focused on two cell lines and may not represent all colon cancer types.
Participant Demographics
The study used human colon carcinoma cell lines (HT29 and HCT116) and nude mice for in vivo experiments.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 0.75–0.87
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website